BRPI0412651A - membro de ligação especìfico isolado para a il-13 humana, domìnios vh e vl de anticorpo isolado, composiçao, ácido nucléico isolado, célula hospedeira, métodos para produzir um membro de ligação especìfico ou domìnio vh ou vl de anticorpo, um domìnio de ligação de antìgeno de anticorpo especìfico para a il-13 humana, um memebro de ligação especìfico que liga a il-13 humana, uso de um membro de ligação especìfico, e, método de tratamento de uma doença de distúrbio - Google Patents

membro de ligação especìfico isolado para a il-13 humana, domìnios vh e vl de anticorpo isolado, composiçao, ácido nucléico isolado, célula hospedeira, métodos para produzir um membro de ligação especìfico ou domìnio vh ou vl de anticorpo, um domìnio de ligação de antìgeno de anticorpo especìfico para a il-13 humana, um memebro de ligação especìfico que liga a il-13 humana, uso de um membro de ligação especìfico, e, método de tratamento de uma doença de distúrbio

Info

Publication number
BRPI0412651A
BRPI0412651A BRPI0412651-3A BRPI0412651A BRPI0412651A BR PI0412651 A BRPI0412651 A BR PI0412651A BR PI0412651 A BRPI0412651 A BR PI0412651A BR PI0412651 A BRPI0412651 A BR PI0412651A
Authority
BR
Brazil
Prior art keywords
human
specific
binding member
antibody
specific binding
Prior art date
Application number
BRPI0412651-3A
Other languages
English (en)
Inventor
Phillip David Monk
Lutz Jermutus
Ralph Raymond Minter
Celia Patricia Shorrock
Original Assignee
Cambridge Antibody Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Antibody Tech filed Critical Cambridge Antibody Tech
Publication of BRPI0412651A publication Critical patent/BRPI0412651A/pt
Publication of BRPI0412651B1 publication Critical patent/BRPI0412651B1/pt
Publication of BRPI0412651B8 publication Critical patent/BRPI0412651B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"MEMBRO DE LIGAçãO ESPECìFICO ISOLADO PARA A IL-13 HUMANA, DOMìNIOS VH E VL DE ANTICORPO ISOLADO, COMPOSIçãO, áCIDO NUCLéICO ISOLADO, CéLULA HOSPEDEIRA, MéTODOS PARA PRODUZIR UM MEMBRO DE LIGAçãO ESPECìFICO OU DOMìMO VH OU VL DE ANTICORPO, UM DOMìNIO DE LIGAçãO DE ANTìGENO DE ANTICORPO ESPECìFICO PARA A IL-13 HUMANA, UM MEMBRO DE LIGAçãO ESPECìFICO QUE LIGA A IL-13 HUMANA, USO DE UM MEMBRO DE LIGAçãO ESPECìFICO, E, MéTODO DE TRATAMENTO DE UMA DOENçA OU DISTúRBIO". Membros de ligação específicos, em particular moléculas de anticorpo anti-IL-13 humanas e especialmente aquelas que neutralizam a atividade de IL- 13. Métodos para usar moléculas de anticorpo anti-IL-13 em diagnóstico ou tratamento de distúrbios relacionados com IL- 13, incluindo asma, dermatite atópica, rinite alérgica, fibrose, doença do intestino inflamatório e linfoma de Hodgkin.
BRPI0412651A 2003-07-15 2004-07-15 molécula de anticorpo isolada para a il-13 humana, composição, ácido nucléico isolado, célula hospedeira, método para produzir uma molécula de anticorpo ou domínio vh ou vl de anticorpo, método para produzir um domínio de ligação de antígeno de anticorpo específico para a il-13 humana, método para produzir uma molécula de anticorpo que liga a il-13 humana, e uso de uma molécula de anticorpo BRPI0412651B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US48751203P 2003-07-15 2003-07-15
US55821604P 2004-03-31 2004-03-31
GBGB0407315.1A GB0407315D0 (en) 2003-07-15 2004-03-31 Human antibody molecules
US57379104P 2004-05-24 2004-05-24
PCT/GB2004/003059 WO2005007699A2 (en) 2003-07-15 2004-07-15 Human antibody molecules for il-13

Publications (3)

Publication Number Publication Date
BRPI0412651A true BRPI0412651A (pt) 2006-09-26
BRPI0412651B1 BRPI0412651B1 (pt) 2020-04-22
BRPI0412651B8 BRPI0412651B8 (pt) 2021-05-25

Family

ID=32298405

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412651A BRPI0412651B8 (pt) 2003-07-15 2004-07-15 molécula de anticorpo isolada para a il-13 humana, composição, ácido nucléico isolado, célula hospedeira, método para produzir uma molécula de anticorpo ou domínio vh ou vl de anticorpo, método para produzir um domínio de ligação de antígeno de anticorpo específico para a il-13 humana, método para produzir uma molécula de anticorpo que liga a il-13 humana, e uso de uma molécula de anticorpo

Country Status (21)

Country Link
US (6) US7829090B2 (pt)
EP (4) EP1646656B1 (pt)
JP (1) JP4891074B2 (pt)
KR (1) KR101168815B1 (pt)
CN (2) CN104987419A (pt)
AT (1) ATE500274T1 (pt)
AU (1) AU2004256976B2 (pt)
BR (1) BRPI0412651B8 (pt)
CA (3) CA2805464A1 (pt)
DE (1) DE602004031622D1 (pt)
DK (1) DK1646656T3 (pt)
ES (1) ES2361079T3 (pt)
GB (2) GB0407315D0 (pt)
IL (1) IL172869A (pt)
NZ (1) NZ544662A (pt)
PL (1) PL1646656T3 (pt)
PT (1) PT1646656E (pt)
RU (1) RU2387667C2 (pt)
SI (1) SI1646656T1 (pt)
WO (1) WO2005007699A2 (pt)
ZA (1) ZA200601340B (pt)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070104710A1 (en) * 2002-06-28 2007-05-10 Domants Limited Ligand that has binding specificity for IL-4 and/or IL-13
US20110223168A1 (en) * 2002-12-27 2011-09-15 Greg Winter Ligand that has binding specificity for il-4 and/or il-13
KR101073590B1 (ko) * 2003-07-15 2011-10-14 메디뮨 리미티드 Ｉｌ-13에 대한 인간 항체 분자
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
EP2280286A1 (en) * 2003-09-15 2011-02-02 Oklahoma Medical Research Foundation Method of using cytokine assays to diagnose, treat, and evaluate systemic lupus erythematosus
MX361174B (es) 2003-12-23 2018-11-29 Genentech Inc Anticuerpos anti-il13 novedosos y sus usos.
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US20070048785A1 (en) * 2004-06-09 2007-03-01 Lin Laura L Anti-IL-13 antibodies and complexes
US20090098142A1 (en) * 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
GB0414799D0 (en) * 2004-07-01 2004-08-04 Glaxo Group Ltd Immunoglobulins
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
WO2006055638A2 (en) 2004-11-17 2006-05-26 Abgenix, Inc. Fully human monoclonal antibodies to il-13
CA2597098C (en) 2005-02-08 2016-08-02 Steven R. Ledbetter Antibodies to tgfbeta
JP4465469B2 (ja) * 2005-02-21 2010-05-19 国立大学法人佐賀大学 循環器病マーカーとしてのインターロイキン１３
US9072716B2 (en) 2005-04-15 2015-07-07 The United States of America, as represented by the Secretary Department of Health by Human Servies Methods of treating and preventing inflammatory bowel disease involving IL-13 and NKT cells
KR101363777B1 (ko) * 2005-09-30 2014-02-14 메디뮨 리미티드 인터루킨―１３ 항체 조성물
EP2532677A1 (en) * 2005-10-21 2012-12-12 Novartis AG Human antibodies against il13 and therapeutic uses
BRPI0710572A2 (pt) * 2006-01-24 2013-01-08 Domantis Limited ligante, uso do ligante, mÉtodos para o tratamento de uma doenÇa alÉrgica, de asma e de cÂncer, para a inibiÇço de uma resposta imune do tipo th2, e administraÇço de tratamento anti-il-4 e tratamento anti-il-13, composiÇço farmacÊutica, dispositivo de dispensaÇço de droga, Ácido nucleico isolado ou recombinante, vetor, cÉlula hospedeira, mÉtodos para a produÇço de um ligante e de inibiÇço da proliferaÇço de cÉlulas
US7943328B1 (en) 2006-03-03 2011-05-17 Prometheus Laboratories Inc. Method and system for assisting in diagnosing irritable bowel syndrome
US20080085524A1 (en) * 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
US20100094560A1 (en) * 2006-08-15 2010-04-15 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
HUE052220T2 (hu) 2006-09-08 2021-04-28 Abbvie Bahamas Ltd Interleukin-13 kötõfehérjék
WO2008048871A2 (en) * 2006-10-18 2008-04-24 Centocor, Inc. Cynomolgus il-13 mutein proteins, antibodies, compositions, methods and uses
US20090068195A1 (en) * 2007-04-23 2009-03-12 Wyeth Methods and compositions for treating and monitoring treatment of il-13-associated disorders
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
NZ601815A (en) * 2008-03-31 2014-10-31 Genentech Inc Compositions and methods for treating and diagnosing asthma
KR20110040886A (ko) 2008-07-08 2011-04-20 아보트 러보러터리즈 프로스타글란딘 ｅ2 결합 단백질 및 이의 용도
EP2328615A2 (en) * 2008-08-20 2011-06-08 Centocor Ortho Biotech Inc. Engineered anti-il-13 antibodies, compositions, methods and uses
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
PL2627673T3 (pl) * 2010-10-15 2018-01-31 Medimmune Ltd Terapie poprawiające funkcje płuc
KR101615420B1 (ko) 2010-12-16 2016-04-26 제넨테크, 인크. Th2 억제에 관한 진단 및 치료
WO2012125775A1 (en) 2011-03-16 2012-09-20 Sanofi Uses of a dual v region antibody-like protein
SG10201505454SA (en) 2011-07-13 2015-09-29 Abbvie Inc Methods and compositions for treating asthma using anti-il-13 antibodies
WO2013087914A1 (en) 2011-12-16 2013-06-20 Synthon Biopharmaceuticals B.V. EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED
HUE037186T2 (hu) 2011-12-28 2018-08-28 Immunoqure Ag Eljárás humán antitestek izolálására
US9550986B2 (en) 2012-12-21 2017-01-24 Abbvie Inc. High-throughput antibody humanization
CA2917112C (en) 2013-07-03 2022-07-05 Immunoqure Ag Human anti-ifn-alpha antibodies
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
PL3044323T3 (pl) 2013-09-13 2022-06-27 F.Hoffmann-La Roche Ag Sposoby wykrywania i ilościowego oznaczania białka komórki gospodarza w liniach komórkowych
SG11201601823TA (en) 2013-09-13 2016-04-28 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
JP6715767B2 (ja) 2013-10-23 2020-07-01 ジェネンテック， インコーポレイテッド 好酸球性疾患の診断及び治療方法
EP3083701B1 (en) 2013-12-17 2019-08-07 Novo Nordisk A/S Enterokinase cleavable polypeptides
HUE064292T2 (hu) 2013-12-26 2024-03-28 Mitsubishi Tanabe Pharma Corp Humán anti-IL-33 semlegesítõ monoklonális antitest
WO2015112970A1 (en) 2014-01-27 2015-07-30 Medimmune, Llc Dipeptidyl peptidase-4 (dpp4/cd26) as a peripheral biomarker of il-13 activation in asthmatic lung
KR20160122756A (ko) 2014-02-07 2016-10-24 메디뮨 엘엘씨 인간 페리오스틴을 검출하기 위한 신규 검정법
JP2017507939A (ja) 2014-02-21 2017-03-23 ジェネンテック， インコーポレイテッド 抗ｉｌ−１３／ｉｌ−１７二重特異性抗体及びその使用
EP3129497B1 (en) 2014-04-11 2021-09-08 Novartis AG Methods of selectively treating asthma using il-13 antagonists
PL3151921T3 (pl) 2014-06-06 2020-02-28 Bristol-Myers Squibb Company Przeciwciała przeciwko receptorowi indukowanego glukokortykoidami czynnika martwicy nowotworu (gitr) i ich zastosowania
BR112016027797A2 (pt) 2014-06-18 2017-10-31 Medimmune Llc métodos e meios de cultura de células compreendendo n-acetilcisteína
AU2016205188A1 (en) 2015-01-09 2017-06-22 Medimmune, Llc Assay to detect human DPP-4
US20160272706A1 (en) * 2015-01-12 2016-09-22 Medimmune Limited Il-13 binding proteins and uses thereof
EP3271723A1 (en) 2015-03-16 2018-01-24 F. Hoffmann-La Roche AG Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases
JP6518917B2 (ja) 2015-05-29 2019-05-29 アッヴィ・インコーポレイテッド 抗ｃｄ４０抗体およびその使用
EP3304079B1 (en) 2015-06-03 2020-06-03 Bristol-Myers Squibb Company Anti-gitr antibodies for cancer diagnostics
MX2018006072A (es) 2015-11-19 2018-08-01 Squibb Bristol Myers Co Anticuerpos contra receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos.
WO2017139290A1 (en) * 2016-02-10 2017-08-17 Medimmune, Llc Tralokinumab delivery device
WO2017189805A1 (en) 2016-04-27 2017-11-02 Abbvie Inc. Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
CN107400165A (zh) * 2016-05-18 2017-11-28 上海开拓者生物医药有限公司 一种il‑13抗体及其制备方法和应用
AU2017295704B2 (en) 2016-07-13 2023-07-13 President And Fellows Of Harvard College Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
WO2018098370A1 (en) 2016-11-23 2018-05-31 Immunoah Therapeutics, Inc. 4-1bb binding proteins and uses thereof
WO2018213297A1 (en) 2017-05-16 2018-11-22 Bristol-Myers Squibb Company Treatment of cancer with anti-gitr agonist antibodies
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
WO2019045075A1 (ja) 2017-08-31 2019-03-07 田辺三菱製薬株式会社 Ｉｌ－３３アンタゴニストを含む子宮内膜症治療剤
CN109810192A (zh) * 2017-11-21 2019-05-28 深圳福沃药业有限公司 抗-il-13抗体
KR20220098056A (ko) 2018-02-09 2022-07-08 제넨테크, 인크. 비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법
GB201802487D0 (en) 2018-02-15 2018-04-04 Argenx Bvba Cytokine combination therapy
EP3830259A4 (en) 2018-08-02 2022-05-04 Dyne Therapeutics, Inc. MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
MA55204A (fr) 2019-03-06 2022-01-12 Regeneron Pharma Inhibiteurs de la voie il-4/il-13 pour une efficacité améliorée dans le traitement du cancer
KR20210143246A (ko) 2019-03-21 2021-11-26 리제너론 파아마슈티컬스, 인크. 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용
US12509512B2 (en) 2019-06-27 2025-12-30 Ramot At Tel-Aviv University Ltd. Semaphorin 3A antibodies and uses thereof
CA3156007A1 (en) 2019-09-27 2021-04-01 Disc Medicine, Inc. METHODS OF TREATING MYELOFIBROSE AND ASSOCIATED CONDITIONS
US20240148891A1 (en) 2019-10-18 2024-05-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
CN114980974A (zh) 2019-12-09 2022-08-30 艾伯霖克斯公司 含靶向il-13和tslp的免疫球蛋白单可变结构域的多肽
AR120698A1 (es) 2019-12-09 2022-03-09 Ablynx Nv Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp
GB201919062D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Antibody
JP7858532B2 (ja) 2020-01-10 2026-05-14 ダイン セラピューティクス，インコーポレーテッド 筋肉標的複合体および筋肉の健康に関連する遺伝子のモジュレーションのためのその使用
EP4126943B1 (en) 2020-03-23 2026-04-22 MedImmune Limited Methods for treating atopic dermatitis and related disorders
CA3097453A1 (en) 2020-03-23 2021-09-23 Medimmune Limited Methods for treating atopic dermatitis and related disorders
ES3075793T3 (en) 2020-05-13 2026-08-07 Disc Medicine Inc Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
US20230340067A1 (en) * 2020-06-26 2023-10-26 St. Jude Children's Research Hospital, Inc. Methods of generating an activation inducible expression system in immune cells
AU2021414227A1 (en) 2020-12-31 2023-07-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
CN112341543B (zh) * 2021-01-11 2021-04-23 广东赛尔生物科技有限公司 包含间充质干细胞外泌体的药物组合物在治疗疾病中的应用
EP4308603A1 (en) 2021-03-17 2024-01-24 Receptos Llc Methods of treating atopic dermatitis with anti il-13 antibodies
CA3217029A1 (en) 2021-05-30 2022-12-08 Biolojic Design Ltd. Engineered dual binding antibodies and uses thereof
GB202108379D0 (en) 2021-06-11 2021-07-28 Medlmmune Ltd Methods for treating a topic dermatitis and related disorders
KR20240046243A (ko) 2021-08-16 2024-04-08 메디뮨 엘엘씨 항-il-13 항체 제제
IL311027A (en) 2021-09-15 2024-04-01 Dermira Inc Il-13 inhibitors for the treatment of prurigo nodularis
EP4408885A1 (en) 2021-09-28 2024-08-07 MedImmune Limited Methods for treating atopic dermatitis and related disorders
EP4433160A1 (en) 2021-11-17 2024-09-25 Disc Medicine, Inc. Methods for treating anemia of kidney disease
JP2025501239A (ja) 2021-12-30 2025-01-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｌ－４／ｉｌ－１３アンタゴニストを投与することによってアトピーマーチを減弱する方法
AU2024229544A1 (en) 2023-03-02 2025-10-16 Alloy Therapeutics, Inc. Anti-cd22 antibodies and uses thereof
AR133647A1 (es) 2023-08-25 2025-10-22 Proteologix Us Inc Constructos de anticuerpos multiespecíficos anti-il-13 y usos de los mismos
CN122374333A (zh) 2023-12-14 2026-07-10 德米拉公司 用于治疗慢性鼻窦炎伴鼻息肉的il-13抗体
AU2024399620A1 (en) 2023-12-14 2026-05-14 Dermira, Inc. Il-13 antibodies for the treatment of perennial allergic rhinitis
TW202600591A (zh) 2024-03-01 2026-01-01 美商德米拉股份有限公司 用於治療發炎後皮膚色素過多或色素過少之ｉｌ—１３抗體
WO2026006494A1 (en) 2024-06-25 2026-01-02 Alloy Therapeutics, Inc. Anti-cd3 antibodies and uses thereof
WO2026006495A1 (en) 2024-06-25 2026-01-02 Alloy Therapeutics, Inc. Anti-wt1/hla-a2 antibody and uses thereof
WO2026006492A2 (en) 2024-06-25 2026-01-02 Ypsilon Therapeutics, Inc. Anti-prame/hla-a2 antibodies and uses thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
EP0656947A1 (en) 1992-08-21 1995-06-14 Schering Corporation Human interleukin-13
CN1085953A (zh) * 1992-08-21 1994-04-27 先灵公司 人白细胞介素13
RU2170589C2 (ru) * 1992-10-28 2001-07-20 Генентек Инк. Композиция для ингибирования ангиогенеза, моноклональное антитело, полипептид, способ ингибирования роста опухоли (варианты)
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US5959085A (en) * 1993-11-23 1999-09-28 Schering Corporation Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
US6664227B1 (en) 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
DE69941267D1 (de) 1998-12-10 2009-09-24 Bristol Myers Squibb Co Proteingerüste für antikörper-nachahmer und andere bindende proteine
US7507706B1 (en) 1998-12-14 2009-03-24 Genetics Institute, Llc Cytokine receptor chain
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
GB0004016D0 (en) 2000-02-22 2000-04-12 Royal Brompton Hospital Biological material and uses thereof
GB2361704C (en) 2000-03-03 2006-08-02 Cambridge Antibody Tech Human antibodies against eotaxin and their use
US20040234499A1 (en) * 2001-10-26 2004-11-25 David Shealy Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses
US20030235555A1 (en) 2002-04-05 2003-12-25 David Shealey Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses
JP2005512522A (ja) * 2001-10-26 2005-05-12 セントカー・インコーポレーテツド Ｉｌ−１３ムテインタンパク質、抗体、組成物、方法および使用
JP4723810B2 (ja) * 2001-12-03 2011-07-13 アレクシオン ファーマシューティカルズ， インコーポレイテッド ハイブリッド抗体
WO2003092610A2 (en) * 2002-05-01 2003-11-13 Regeneron Pharmaceuticals, Inc. Methods of using cytokine antagonists to treat hiv infection and aids
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
MX361174B (es) 2003-12-23 2018-11-29 Genentech Inc Anticuerpos anti-il13 novedosos y sus usos.
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
WO2006055638A2 (en) 2004-11-17 2006-05-26 Abgenix, Inc. Fully human monoclonal antibodies to il-13
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Also Published As

Publication number Publication date
US20120052060A1 (en) 2012-03-01
SI1646656T1 (sl) 2011-07-29
US9856317B2 (en) 2018-01-02
BRPI0412651B1 (pt) 2020-04-22
US9315575B2 (en) 2016-04-19
DK1646656T3 (da) 2011-05-30
DE602004031622D1 (de) 2011-04-14
PL1646656T3 (pl) 2011-08-31
GB2403952C2 (en) 2013-02-13
KR101168815B1 (ko) 2012-07-27
US20090123478A1 (en) 2009-05-14
AU2004256976B2 (en) 2010-12-23
CA2804901C (en) 2018-04-24
EP2292660A2 (en) 2011-03-09
EP2292660B1 (en) 2016-07-06
US7829090B2 (en) 2010-11-09
RU2387667C2 (ru) 2010-04-27
ZA200601340B (en) 2008-12-31
JP2007537702A (ja) 2007-12-27
US7935343B2 (en) 2011-05-03
GB2403952C (en) 2006-06-16
KR20110023914A (ko) 2011-03-08
US20160280779A1 (en) 2016-09-29
GB2403952B (en) 2005-09-21
EP2292660A3 (en) 2011-10-12
GB0415857D0 (en) 2004-08-18
BRPI0412651B8 (pt) 2021-05-25
CA2804901A1 (en) 2005-01-27
WO2005007699A3 (en) 2005-05-12
EP2314624B1 (en) 2016-05-04
CA2805464A1 (en) 2005-01-27
CN1852923B (zh) 2015-05-27
US7947273B2 (en) 2011-05-24
CN1852923A (zh) 2006-10-25
PT1646656E (pt) 2011-06-07
EP1646656A2 (en) 2006-04-19
CA2532799A1 (en) 2005-01-27
EP1646656B1 (en) 2011-03-02
JP4891074B2 (ja) 2012-03-07
RU2006104618A (ru) 2007-08-27
CN104987419A (zh) 2015-10-21
GB0407315D0 (en) 2004-05-05
ATE500274T1 (de) 2011-03-15
US20180230209A1 (en) 2018-08-16
EP2314624A3 (en) 2011-06-29
GB2403952A (en) 2005-01-19
US20070128192A1 (en) 2007-06-07
IL172869A (en) 2013-10-31
EP3064510A1 (en) 2016-09-07
US20050065327A1 (en) 2005-03-24
AU2004256976A1 (en) 2005-01-27
NZ544662A (en) 2009-09-25
CA2532799C (en) 2013-04-02
EP2314624A2 (en) 2011-04-27
WO2005007699A2 (en) 2005-01-27
ES2361079T3 (es) 2011-06-13
IL172869A0 (en) 2006-06-11
WO2005007699A8 (en) 2005-10-27

Similar Documents

Publication Publication Date Title
BRPI0412651B8 (pt) molécula de anticorpo isolada para a il-13 humana, composição, ácido nucléico isolado, célula hospedeira, método para produzir uma molécula de anticorpo ou domínio vh ou vl de anticorpo, método para produzir um domínio de ligação de antígeno de anticorpo específico para a il-13 humana, método para produzir uma molécula de anticorpo que liga a il-13 humana, e uso de uma molécula de anticorpo
HRP20110758T1 (en) Il-17 antagonistic antibodies
ATE414151T1 (de) Antikörper gegen eotaxin und deren verwendung
HRP20171765T1 (hr) Protutijela koja vežu il-4 i/ili il-13 i njihova uporaba
WO2003060080A3 (en) Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
CY1117702T1 (el) Πρωτεϊνες δεσμευομενες με αντιγονο ικανες να δεσμευονται με θυμικη στρωματικη λεμφοποιητινη
WO2013056851A3 (en) Stable multiple antigen-binding antibody
GEP20125471B (en) Compositions monovalent for cd40l binding and methods of use
NZ588713A (en) Antibodies to receptor of advanced glycation end products (rage) and uses thereof
GEP20115226B (en) P-cadherin antibodies
UA99701C2 (ru) Человеческое моноклональное антитело, которое специфически связывается с лигандом-1 запрограммированной гибели клеток (pd-l1)
AR035581A1 (es) Anticuerpos para il-1beta humana
DE60130538D1 (de) Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
EP4353819A3 (en) Binding molecules
RU2007139953A (ru) Антитела к ccr5 и их применение
ATE490983T1 (de) Humane antikörper gegen das humane glycoprotein vi und deren verwendung
Ahmed Immunoglobulins: Structure, function, and therapeutic applications in immune response
KR940006602A (ko) 면역글로불린 이소타입에 대한 재조형 모노클로날 항체
Wu et al. Identification of low molecular weight allergens of American cockroach and production of monoclonal antibodies
Ahmed Immunoglobulins: Structure, Function, and Therapeutic Applications in Immune
TH153130A (th) แอนทิบอดีแอนทิ-TSLP ซึ่งถูกทำวิศวกรรม (Engineered anti-TSLP antibody)
TH90390B (th) โมเลกุลของแอนติบอดีที่มีความจำเพาะกับ il-6 ของคน

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: MEDIMMUNE LIMITED (GB)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 22/04/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/07/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2840 DE 10-06-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.